Efficacy and safety of switching from entecavir to tenofovir alafenamide in chronic hepatitis B patients with low-level viremia: a real-world 48-week extension study.
He M-W, Cui L, Chen D-D, Zhao Y, Luo W-Z, Jia Y-F, Zhou J, He Q-J, Dai Y, Zhang W-H, Yu Z-X, Wang W-C, Guo C, Fu Y-M, Yang W-C, Li X-Y, Guo Y-F, Wang C-Y, Wang J-J, Li P, Qiao B, Ji D, Li Z-B.
He M-W, et al. Among authors: guo c.
Antimicrob Agents Chemother. 2025 Feb 4:e0182724. doi: 10.1128/aac.01827-24. Online ahead of print.
Antimicrob Agents Chemother. 2025.
PMID: 39902928